{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:32:52Z","timestamp":1785450772767,"version":"3.56.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81770686"],"award-info":[{"award-number":["81770686"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81970591 to M.H."],"award-info":[{"award-number":["81970591 to M.H."]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["81670633 to G.X."],"award-info":[{"award-number":["81670633 to G.X."]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study was designed to evaluate the efficiency and safety of combination therapy with sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors and renin\u2013angiotensin system blockers such as angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched the PubMed, Embase, Web of Science and Cochrane Library databases from their inception to May 2020. Two authors independently performed study selection, risk-of-bias assessment and data extraction. The quality and risk of bias were assessed by the Cochrane Risk of Bias Tool. Statistical heterogeneity was determined by the I2 statistics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven studies including 1757 patients were analysed. Compared with ACEI\/ARB alone, combination therapy with SGLT2 inhibitors and ACEIs\/ARBs produced a reduction in systolic blood pressure (SBP) [weighted mean difference (WMD) \u22123.84\u2009mmHg], diastolic blood pressure (DBP; WMD \u22121.06\u2009mmHg), 24\u2009h ambulatory SBP (WMD \u22124.59\u2009mmHg), 24-h ambulatory DBP (WMD \u22122.08\u2009mmHg), urine albumin:creatinine ratio (WMD \u221229.70%), evaluated glomerular filtration rate (WMD \u22123.46\u2009mL\/min\/1.73\u2009m2), haemoglobin A1c [standardized mean difference (SMD) \u22120.48], fasting plasma glucose (SMD \u22120.28), uric acid (SMD \u22120.35) and body weight (SMD \u22120.29). The risk of hypoglycaemia with combination therapy was higher than in the control group (risk ratio 1.37). As for the risks of total adverse events, genital infection and urinary tract infection, no significant difference was revealed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Compared with ACEI\/ARB alone, the combination therapy with SGLT2 inhibitors and ACEIs\/ARBs in T2DM was effective and well-tolerated and could achieve additional effects including better control of blood pressure, improvement of renal outcomes, alleviation of long-term renal function and a decrease in blood glucose and body weight. The combination therapy showed an increased risk of hypoglycaemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfab048","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T21:19:20Z","timestamp":1613510360000},"page":"720-729","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of combination therapy with sodium\u2013glucose cotransporter 2 inhibitors and renin\u2013angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"37","author":[{"given":"Beichen","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjun","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"2022032512311674900_gfab048-B1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.cell.2012.02.010","article-title":"Diabetes mellitus and the \u03b2 cell: the last ten years","volume":"148","author":"Ashcroft","year":"2012","journal-title":"Cell"},{"key":"2022032512311674900_gfab048-B2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"2022032512311674900_gfab048-B3","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","article-title":"Type 2 diabetes mellitus","volume":"1","author":"DeFronzo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2022032512311674900_gfab048-B4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","article-title":"Diabetes and hypertension: the bad companions","volume":"380","author":"Ferrannini","year":"2012","journal-title":"Lancet"},{"key":"2022032512311674900_gfab048-B5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrendo.2016.209","article-title":"Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME","volume":"13","author":"Sarafidis","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2022032512311674900_gfab048-B6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.maturitas.2018.03.013","article-title":"Hypertension in patients with type 2 diabetes mellitus: targets and management","volume":"112","author":"Pavlou","year":"2018","journal-title":"Maturitas"},{"key":"2022032512311674900_gfab048-B7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.beem.2016.06.001","article-title":"Managing hypertension in type 2 diabetes mellitus","volume":"30","author":"Horr","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2022032512311674900_gfab048-B8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41440-018-0034-4","article-title":"Hypertension with diabetes mellitus: physiology and pathology","volume":"41","author":"Ohishi","year":"2018","journal-title":"Hypertens Res"},{"key":"2022032512311674900_gfab048-B9","first-page":"341","article-title":"Managing hypertension using combination therapy","volume":"101","author":"Smith","year":"2020","journal-title":"Am Fam Physician"},{"key":"2022032512311674900_gfab048-B10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2022032512311674900_gfab048-B11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41581-019-0135-6","article-title":"Epigenetics and epigenomics in diabetic kidney disease and metabolic memory","volume":"15","author":"Kato","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2022032512311674900_gfab048-B12","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2022032512311674900_gfab048-B13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S2213-8587(18)30263-8","article-title":"New pharmacological strategies for protecting kidney function in type 2 diabetes","volume":"7","author":"Muskiet","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022032512311674900_gfab048-B14","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2014.74","article-title":"Therapeutic approaches to diabetic nephropathy\u2014beyond the RAS","volume":"10","author":"Fernandez-Fernandez","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2022032512311674900_gfab048-B15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.2174\/15733998113096660085","article-title":"Type 2 diabetes mellitus and Invokana: an FDA approved drug","volume":"9","author":"Akhtar","year":"2013","journal-title":"Curr Diabetes Rev"},{"key":"2022032512311674900_gfab048-B16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022032512311674900_gfab048-B17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2337\/dc18-1871","article-title":"Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an analysis of the placebo arm of EXSCEL","volume":"42","author":"Clegg","year":"2019","journal-title":"Diabetes Care"},{"key":"2022032512311674900_gfab048-B18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"2022032512311674900_gfab048-B19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"key":"2022032512311674900_gfab048-B20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2022032512311674900_gfab048-B21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"2022032512311674900_gfab048-B22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium\u2013glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"2022032512311674900_gfab048-B23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s13300-018-0471-8","article-title":"SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice","volume":"9","author":"Wilding","year":"2018","journal-title":"Diabetes Ther"},{"key":"2022032512311674900_gfab048-B24","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2022032512311674900_gfab048-B25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/dom.12322","article-title":"Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus","volume":"16","author":"Sha","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2022032512311674900_gfab048-B26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/jch.12747","article-title":"Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment of canagliflozin in patients with type 2 diabetes mellitus and hypertension","volume":"18","author":"Townsend","year":"2015","journal-title":". J Clin Hypertens"},{"key":"2022032512311674900_gfab048-B27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3109\/08037051.2015.1116258","article-title":"Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin\u2013angiotensin system blockade","volume":"25","author":"Weber","year":"2016","journal-title":"Blood Press"},{"key":"2022032512311674900_gfab048-B28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","article-title":"Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study","volume":"4","author":"Weber","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022032512311674900_gfab048-B29","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/dom.12936","article-title":"The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients","volume":"19","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022032512311674900_gfab048-B30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"2022032512311674900_gfab048-B31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S2213-8587(19)30086-5","article-title":"Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Pollock","year":"2019","journal-title":"Lancet Diab Endocrinol"},{"key":"2022032512311674900_gfab048-B32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00041552-200007000-00012","article-title":"Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers","volume":"9","author":"Weir","year":"2000","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2022032512311674900_gfab048-B33","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","article-title":"A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation","volume":"16","author":"Ott","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2022032512311674900_gfab048-B34","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/dom.12962","article-title":"Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension","volume":"19","author":"Chilton","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2022032512311674900_gfab048-B35","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1161\/CIRCULATIONAHA.118.036568","article-title":"Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension","volume":"139","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"key":"2022032512311674900_gfab048-B36","doi-asserted-by":"crossref","first-page":"e0165703","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium\u2013glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin\u2013angiotensin system in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"key":"2022032512311674900_gfab048-B37","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium\u2013glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2022032512311674900_gfab048-B38","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022032512311674900_gfab048-B39","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1681\/ASN.2019010064","article-title":"Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS program","volume":"30","author":"Neuen","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022032512311674900_gfab048-B40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jdi.12971","article-title":"Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME\u00ae trial","volume":"10","author":"Kadowaki","year":"2019","journal-title":"J Diabetes Investig"},{"key":"2022032512311674900_gfab048-B41","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2022032512311674900_gfab048-B42","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11255-019-02112-6","article-title":"Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials","volume":"51","author":"Feng","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"2022032512311674900_gfab048-B43","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"2022032512311674900_gfab048-B44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin\u2013angiotensin\u2013aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"2022032512311674900_gfab048-B45","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"2022032512311674900_gfab048-B46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes Obes Metab"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfab048\/36738239\/gfab048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/4\/720\/42973035\/gfab048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/4\/720\/42973035\/gfab048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T17:01:18Z","timestamp":1648227678000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/4\/720\/6144902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,19]]},"published-print":{"date-parts":[[2022,3,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfab048","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4]]},"published":{"date-parts":[[2021,2,19]]}}}